Kidney transplant medication is one of the realities of life after surgery that anyone who has been through it understands. The transplant itself is the gift, but the daily routine of anti-rejection tablets that comes with it is part of every day for the rest of a patient’s life. New research from the University of California, San Francisco hints that this part of the journey could change.
How kidney transplant medication could change
A phase 2 pilot study, published on 3 February 2026 in the American Journal of Transplantation, tested whether two newer drugs given by infusion could replace the everyday kidney transplant medication that patients currently take by mouth. Twenty-three patients received infusions of two proteins, belatacept and dazodalibep, which work by quietly damping down the immune system’s attack on the new kidney without affecting other cells in the body in the way standard tablets often do.
Each patient started on the usual tablets after their transplant, then by day 28 they moved fully onto the infusions for the remainder of the 48-week study. According to UCSF, kidney function improved across the patients who completed the trial, and importantly there were no cases of rejection caused by antibodies. Antibody-mediated rejection is one of the most serious threats to a transplanted kidney over time, so this is an encouraging early signal.
The trial was not without setbacks. Two of the first three patients did experience rejection, which the medical team treated successfully and reversed. The dose and frequency were then adjusted, and thirteen of the patients went on to complete the full study. Seven withdrew, either because of rejection, side effects, or reasons not specified in the published paper.
Why this matters to transplant patients
For transplant patients, the appeal of a monthly infusion over multiple daily tablets is easy to understand. The first author, Professor Flavio Vincenti of UCSF, was clear that he hopes the simpler regimen would help with one of the long-standing problems in transplant medicine: patients sometimes skipping doses because the tablets are difficult to live with. Standard immunosuppressants can contribute to diabetes, high blood pressure, raised cholesterol, weight gain, fatigue, muscle weakness, hair loss, and other effects that wear people down over the years.
Anything that protects the new kidney while also lifting some of that weight from daily life would be a real step forward, and a simpler kidney transplant medication routine would also support the wider goal of keeping the donor kidney working well for as long as possible. There is already careful work supported by Kidney Research UK and other UK groups going on across the country to improve anti-rejection therapy for kidney transplant patients, and the UCSF results add another encouraging chapter to that story. They also sit alongside other recent research, including the CMV vaccine work helping transplant patients manage immune challenges, which we wrote about earlier this year.
What still needs to happen
This was a small phase 2 pilot, not a final answer. The senior author, Professor Allan D. Kirk of Duke University School of Medicine, was clear that the next step is a much larger trial to see whether these early findings hold up across many more patients.
Routine clinical use is still several years away, and any move into routine UK transplant care would also involve NHS Blood and Transplant alongside national regulators, and the precise role of the new approach, whether it becomes a first-line option or one reserved for particular patients, will only become clear after that larger study. Alongside drug research, other UK and international teams are also looking at tools to boost kidney transplant success rates, all aiming at the same goal of giving the new organ the longest possible life.
It is worth saying too that the research is at an early stage in the United States and has not yet been tested here in the UK, where parallel transplant work such as the Oxford ADMIRE kidney transplant study is exploring different ways to improve outcomes after surgery. Any patient curious about the implications for their own care should always speak with their renal team, and we always encourage members to take any new article like this one as a reason for an honest conversation, not a change in treatment plan.
You can read more about the team at renal care at Manchester Royal Infirmary on our site.
Daily medication is one of the realities of life after transplant that we don’t always talk about. Anything that gives patients a simpler, kinder regimen while still protecting the new kidney is worth keeping an eye on, and we will continue to follow this work as it progresses.
Guy Hill, Chair of MRIKPA
If you have recently had a transplant, are waiting for one, or care for someone going through it, we know how much these everyday details matter. You are welcome to share your own experience with us at our patient stories page, or get in touch at support@mrikpa.org.uk or 07745 242 684. We are a small community of patients in Manchester who know what life with a transplant can feel like, and we are always happy to listen.
Source: UCSF News, 3 February 2026: New Therapy Could Make Life Better for Kidney Transplant Patients. Original study by Vincenti F, Kirk AD, and colleagues in the American Journal of Transplantation.
